Claude C. Schulman

PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4: WHEN SHOULD WE STOP?

Bob Djavan, V. Ravery, A. Zlotta et al. · The Journal of Urology · 2001 · 448 citations

Medicine, Oncology, Urology +17

Radiofrequency Interstitial Tumor Ablation (RITA) Is a Possible New Modality for Treatment of Renal Cancer: <i>Ex Vivo</i> and <i>in Vivo</i> Experience

Alexandre R. Zlotta, T Wildschutz, Gil Raviv et al. · Journal of Endourology · 1997 · 376 citations

Medicine, Oncology, Genitourinary Oncology +11

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Michael A. Carducci, Robert J. Padley, Jürgen Breul et al. · Journal of Clinical Oncology · 2003 · 370 citations

Medicine, Oncology, Pharmacology +16

OPTIMAL PREDICTORS OF PROSTATE CANCER ON REPEAT PROSTATE BIOPSY: A PROSPECTIVE STUDY OF 1,051 MEN

Bob Djavan, Alexandre R. Zlotta, Mesut Remzi et al. · The Journal of Urology · 2000 · 324 citations

Medicine, Oncology, Urology +16

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer

Michael A. Carducci, Fred Saad, Per‐Anders Abrahamsson et al. · Cancer · 2007 · 292 citations

Medicine, Oncology, Pharmacology +17